Dr. Jae-Hyuck Shim's lab focuses on understanding and treating bone loss diseases, particularly in the context of inflammatory arthritis and osteogenesis imperfecta (a genetic disorder leading to fragile bones). They develop innovative gene therapies using specialized viruses to enhance bone health by targeting specific proteins that regulate bone formation. Through their research, they aim to discover new treatments that could improve patient outcomes in these conditions.

The research lab of Job Dekker at the University of Massachusetts Medical School focuses on understanding how the human genome is organized and regulated. His team investigates how the three-dimensional structure of chromosomes affects gene expression and stability, and how defects in this organization can lead to diseases such as cancer. By employing cutting-edge genomic technologies, they explore the molecular mechanisms that facilitate proper chromosome folding and segregation during the cell cycle.

Dr. Toloo Taghian's lab is focused on developing innovative gene therapy approaches for treating UBA5 deficiency, a rare genetic disorder that causes severe neurological issues in children. Using a newly created mouse model that mimics the human disease, the lab aims to understand the underlying mechanisms of UBA5 deficiency and test promising gene therapy strategies to potentially rescue neurological functions. Their research could pave the way for effective treatments for patients suffering from this deadly condition.

Dr. Heather L Gray-Edwards leads research focusing on innovative gene therapies for severe genetic disorders such as Maple Syrup Urine Disease (MSUD) and Sialidosis. Her lab utilizes animal models, including mice and sheep, to test adeno-associated virus (AAV) gene therapies that aim to correct underlying biochemical issues and alleviate associated neurological symptoms. The overarching goal is to develop effective treatments that can prevent the severe complications often seen in these disorders, ultimately paving the way for future clinical applications in human medicine.

Dr. Erik J. Sontheimer's lab focuses on developing cutting-edge genetic editing technologies to treat diseases, specifically frontotemporal dementia caused by granulin mutations. The team uses precision genome editing techniques like base and prime editing to accurately correct genetic mutations in neuronal cells and evaluate their effectiveness in mouse models. This innovative approach aims to create safer and more effective therapies for neurological disorders that currently lack treatment options.

Dr. Amir Mitchell's lab at the University of Massachusetts Medical School focuses on understanding how certain drugs not typically classified as antibiotics can negatively impact the gut microbiome by causing bacterial cells to become resistant. By studying the mechanisms of bacterial toxicity and resistance using E. coli as a model organism, the lab aims to uncover the pathways affected by these drugs. This research is vital because it sheds light on how commonly prescribed medications may contribute to antibiotic resistance and microbiome dysbiosis, highlighting the importance of balanced drug use for human health.

Dr. Anastasia Khvorova's lab at the University of Massachusetts focuses on creating new types of therapy using small pieces of genetic material called oligonucleotides. These therapies target and reduce the expression of harmful genes related to neurodegenerative diseases like Huntington's disease and ALS. The lab is working on improving the delivery of these therapies to the central nervous system to make them more effective and longer-lasting.

Dr. Guangping Gao's lab focuses on developing targeted gene therapies to treat rare neurological disorders, specifically those affecting oligodendrocytes, which are crucial for healthy brain function. Their research primarily addresses conditions like Canavan disease and other leukodystrophies, employing innovative adeno-associated virus (AAV) strategies to improve the safety and effectiveness of gene therapy in these diseases. By understanding how AAV interacts with oligodendrocytes, the lab aims to enhance gene delivery systems tailored to these specific cell types.

Dr. Athma A. Pai's lab at the University of Massachusetts Medical School focuses on understanding how genes control the production of different RNA molecules from the same gene. They use advanced techniques to measure how quickly RNA is made and processed, which helps to explain the variety of RNA molecules found in different cells. This research is important for uncovering how genetic differences can affect human health and disease.

Dr. Andrei Korostelev's lab focuses on understanding ribosomes, the protein-synthesizing machinery in cells, and their regulatory roles in various biological processes. The research aims to uncover how ribosomes respond to cellular stress, influence neurodevelopment, and manage the production of proteins that are crucial for blood vessel growth. By employing advanced biophysical techniques, the lab seeks to elucidate the mechanisms behind these processes and their implications for treating diseases such as amyotrophic lateral sclerosis and cardiovascular issues.

Dr. Phillip Tai's lab at the University of Massachusetts Medical School focuses on improving adeno-associated virus (AAV) gene therapies by studying specific genetic sequences known as inverted terminal repeats (ITRs). They explore how variations in these sequences may impact the effectiveness and safety of gene therapies for genetic diseases. Their research combines advanced sequencing methods and animal models to uncover important insights that could lead to safer and more effective treatments.

Dr. A. J. Marian Walhout's research lab focuses on understanding how metabolism and gene expression interact in living organisms, particularly using the model organism C. elegans, a small roundworm. By investigating how genetic mutations and dietary factors affect metabolic processes and gene activity, the lab aims to shed light on the mechanisms behind various human diseases. This research not only explores basic biological principles but also has the potential to inform treatments for metabolic disorders in humans.

Dr. Jonathan K Watts' lab is focused on developing innovative therapies for neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS). The research is centered around RNA-targeted medicine, utilizing advanced techniques to create safer and more effective drug candidates that can silence multiple disease-related genes. By combining expertise in neurology with cutting-edge chemistry, the lab aims to improve treatment options for patients with ALS and similar disorders.

Dr. Wen Xue's research lab focuses on creating advanced mouse models of cancer using innovative genome editing techniques, specifically prime editing. Their goal is to better understand how genetic mutations contribute to cancer development and treatment resistance. By optimizing tools for precise genetic modifications, the lab aims to produce more accurate cancer models that can help identify effective therapies and biomarkers.